Your browser doesn't support javascript.
loading
Evaluation of Cerebrospinal Fluid α-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome.
Vaughan, David P; Fumi, Riona; Theilmann Jensen, Marte; Hodgson, Megan; Georgiades, Tatiana; Wu, Lesley; Lux, Danielle; Obrocki, Ruth; Lamoureux, Jennifer; Ansorge, Olaf; Allinson, Kieren S J; Warner, Thomas T; Jaunmuktane, Zane; Misbahuddin, Anjum; Leigh, P Nigel; Ghosh, Boyd C P; Bhatia, Kailash P; Church, Alistair; Kobylecki, Christopher; Hu, Michele T M; Rowe, James B; Blauwendraat, Cornelis; Morris, Huw R; Jabbari, Edwin.
Afiliación
  • Vaughan DP; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Fumi R; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Theilmann Jensen M; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Hodgson M; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Georgiades T; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Wu L; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Lux D; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Obrocki R; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Lamoureux J; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Ansorge O; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Allinson KSJ; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Warner TT; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Jaunmuktane Z; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Misbahuddin A; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Leigh PN; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Ghosh BCP; Movement Disorders Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Bhatia KP; Amprion Inc., San Francisco, California, USA.
  • Church A; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
  • Kobylecki C; Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom.
  • Hu MTM; Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Rowe JB; Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Blauwendraat C; Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Morris HR; Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Jabbari E; Department of Neurology, Queen's Hospital, Romford, United Kingdom.
Mov Disord ; 2024 Sep 20.
Article en En | MEDLINE | ID: mdl-39301998
ABSTRACT

BACKGROUND:

Seed amplification assay (SAA) testing has been developed as a biomarker for the diagnosis of α-synuclein-related neurodegenerative disorders.

OBJECTIVE:

The objective of this study was to assess the rate of α-synuclein SAA positivity in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) and to analyze clinical and pathological features of SAA-positive and -negative cases.

METHODS:

A total of 96 cerebrospinal fluid samples from clinically diagnosed PSP (n = 59) and CBS (n = 37) cases were analyzed using α-synuclein SAA.

RESULTS:

Six of 59 (10.2%) PSP cases were α-synuclein SAA positive, including one case who was MSA-type positive. An exploratory analysis showed that PSP cases who were Parkinson's disease-type positive were older and had a shorter disease duration compared with SAA-negative cases. In contrast, 11 of 37 (29.7%) CBS cases were α-synuclein SAA positive, including two cases who were MSA-type positive.

CONCLUSIONS:

Our results suggest that α-synuclein seeds can be detected in PSP and CBS using a cerebrospinal fluid α-synuclein SAA, and in PSP this may impact on clinical course. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos